Becton, Dickinson and Company (BDX)
Automate Your Wheel Strategy on BDX
With Tiblio's Option Bot, you can configure your own wheel strategy including BDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BDX
- Rev/Share 76.9027
- Book/Share 88.6855
- PB 2.0786
- Debt/Equity 0.7728
- CurrentRatio 1.0489
- ROIC 0.0475
- MktCap 66785476522.0
- FreeCF/Share 9.2292
- PFCF 25.3841
- PE 29.9093
- Debt/Assets 0.3563
- DivYield 0.0178
- ROE 0.0693
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | BDX | Barclays | -- | Overweight | -- | $202 | Feb. 10, 2026 |
| Resumed | BDX | Citigroup | -- | Buy | -- | $233 | Feb. 3, 2026 |
| Initiation | BDX | RBC Capital Mkts | -- | Sector Perform | -- | $211 | Sept. 25, 2025 |
| Downgrade | BDX | Citigroup | Buy | Neutral | -- | $185 | May 22, 2025 |
| Downgrade | BDX | Goldman | Buy | Neutral | -- | $192 | May 2, 2025 |
| Downgrade | BDX | Piper Sandler | Overweight | Neutral | -- | $185 | May 2, 2025 |
| Downgrade | BDX | Raymond James | Outperform | Market Perform | -- | -- | May 2, 2025 |
| Downgrade | BDX | William Blair | Outperform | Market Perform | -- | -- | May 1, 2025 |
| Downgrade | BDX | BofA Securities | Buy | Neutral | -- | $190 | May 1, 2025 |
| Downgrade | BDX | Wells Fargo | Overweight | Equal Weight | -- | -- | May 1, 2025 |
News
BD Launches Urine Complete Cup Kit for Smarter Testing & Accuracy
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Positive
BDX launches a three-tube urine collection kit to expand testing from one sample, aiming to boost lab efficiency and reduce contamination risks.
Read More
BD Expands Testing Capabilities to Help Clinicians Improve Diagnostic Accuracy and Efficiency
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
The BD Vacutainer® Urine Complete Cup Kit preserves specimen quality, streamlines testing, and helps reduce repeat collections to support better patient care FRANKLIN LAKES, N.J., Feb. 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Vacutainer® Urine Complete Cup Kit, a three-tube collection system that expands and supports broader testing capabilities from a single urine specimen.
Read More
BD Merges Biosciences & Diagnostics Business With Waters
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Neutral
BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play MedTech focus.
Read More
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
Published: February 10, 2026 by: PRNewsWire
Sentiment: Neutral
FRANKLIN LAKES, N.J., Feb. 10, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) (the "Company" or "BD"), a leading global medical technology company, today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series").
Read More
Becton, Dickinson and Company (BDX) Q1 2026 Earnings Call Transcript
Published: February 09, 2026 by: Seeking Alpha
Sentiment: Neutral
Becton, Dickinson and Company (BDX) Q1 2026 Earnings Call Transcript
Read More
BD Stock Dips in Pre-Market Despite Q1 Earnings Beat, Margins Up
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
BDX posts an earnings beat with revenue growth and expanding margins in first-quarter fiscal 2026 quarter, though adjusted profit declined year over year.
Read More
Can Sustained Product Demand Drive BDX Stock Before Q1 Earnings?
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Negative
BD rides on sustained product demand across Medical, Life Sciences and Interventional, but China market dynamics may pressure first-quarter fiscal 2026 results.
Read More
Countdown to Becton Dickinson (BDX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Becton Dickinson (BDX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
BD & Envetec Showcase Closed-Loop Recycling Solution for Lab Plastics
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
BDX completes a pilot with Envetec showing polystyrene Petri dishes can be safely recycled into new medical-grade feedstock.
Read More
Earnings Preview: Becton Dickinson (BDX) Q1 Earnings Expected to Decline
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Negative
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
10 Highest Rated Dividend Kings For Generations Of Income
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Positive
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend safety/growth grades, and favorable Quant, SA, and Wall Street ratings. ABM Industries leads with a low 31% payout ratio, 2.5% yield, B- safety/growth, and an A- valuation grade despite a Hold Quant rating.
Read More
BDX Introduces BD Research Cloud 7.0 for Advanced Flow Cytometry
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
BD launches BD Research Cloud 7.0 with AI-powered Horizon Panel Maker, boosting automation, data intelligence and productivity in flow cytometry.
Read More
BDX vs. SAUHY: Which Stock Is the Better Value Option?
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
BD to Announce Financial Results for its First Quarter of Fiscal 2026
Published: January 27, 2026 by: PRNewsWire
Sentiment: Neutral
FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
Read More
BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business
Published: January 27, 2026 by: PRNewsWire
Sentiment: Neutral
Distribution date and closing date for spin-off and merger with Waters Corporation set for February 9, 2026 FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) ("BD" or the "Company") today announced that the Company's Board of Directors has set the close of business on February 5, 2026, as the record date for the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business to BD's shareholders.
Read More
Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
Published: January 27, 2026 by: PRNewsWire
Sentiment: Neutral
Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE: BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters.
Read More
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
BD and Ypsomed Expand Partnership to Target Growing Biologics Market
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
BDX expands its Ypsomed partnership with a 5.5 mL Neopak XtraFlow syringe, targeting rising demand for large-volume subcutaneous self-injection.
Read More
BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
BDX wins FDA 510(k) clearance for the EnCor EnCompass breast biopsy system, set for an early 2026 launch to boost flexibility and patient care.
Read More
Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026
Published: January 15, 2026 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration on Thursday granted 510(k) clearance for Becton, Dickinson and Company's (NYSE: BDX) new breast biopsy system.
Read More
Waters Corporation Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT
Published: January 07, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Read More
Why The ‘Magnificent 7' Is Out In 2026 And These 3 Dividends Are ‘In'
Published: January 07, 2026 by: Forbes
Sentiment: Neutral
Ignore the doom-and-gloom “predictions” about 2026. There are plenty of gains—and growing dividends—to be had for us this year.
Read More
Best Dividend Aristocrats For January 2026
Published: December 31, 2025 by: Seeking Alpha
Sentiment: Positive
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
Read More
BD and Penn Institute Ink Collaboration to Advance Immunotherapy
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
BDX teams up with the Penn Institute for Immunology and Immune Health to launch a high-parameter immune profiling study.
Read More
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
The Magnificent 7 Are So Yesterday. These Are AI's Next Big Winners
Published: December 17, 2025 by: Forbes
Sentiment: Positive
Today I have a sweet dividend “double shot” for you: The first? A 2.8% payout set to grow thanks to AI—and take the stock price up with it.
Read More
BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
BDX expands its BD MAX menu in Europe with IVDR-approved respiratory and STI assays, boosting system utility and reinforcing its diagnostics growth strategy.
Read More
BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.
Read More
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
About Becton, Dickinson and Company (BDX)
- IPO Date 1973-02-21
- Website https://www.bd.com
- Industry Medical - Instruments & Supplies
- CEO Thomas E. Polen Jr.
- Employees 70000